Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout

Another day, another delay. On Monday, Roche revealed that in addition to the US Federal Trade Commission, the UK’s Competition and Markets Authority is probing the Spark Therapeutics takeover deal, triggering another delay of the $4.3 billion acquisition announced in February.